Serum Ferritin as a Non-invasive Marker in Prediction of Hepatic Fibrosis Among NAFLD Patients
1 other identifier
observational
113
0 countries
N/A
Brief Summary
This study was designed to assess the relation between serum ferritin and hepatic fibrosis in patients with NAFLD. It included 83 patients with NAFLD with or without hepatic fibrosis, in addition to 30 healthy subjects included as controls. Measurement of serum ferritin and its correlation with steatosis and fibrosis was done.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2015
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2016
CompletedFirst Submitted
Initial submission to the registry
August 8, 2017
CompletedFirst Posted
Study publicly available on registry
August 15, 2017
CompletedAugust 15, 2017
August 1, 2017
1.1 years
August 8, 2017
August 12, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Serum ferritin in patients with hepatic fibrosis on top of NAFLD
measurement of serum ferritin in patients with hepatic fibrosis on top NAFLD in comparison with normal control and simple steatosis
1 year
Study Arms (3)
control group
NAFLD patients without hepatic fibrosis
NAFLD patients with hepatic fibrosis
Interventions
serum samples and ferritin ELISA test
Eligibility Criteria
Group I: included 30 healthy subjects as control. Group II: included 31 patients with NAFLD without liver fibrosis. Group III: included 52 patients with hepatic fibrosis on top of NAFLD.
You may qualify if:
- adult patients with NAFLD with or without hepatic fibrosis
You may not qualify if:
- Significant alcohol consumption, other causes of liver disease such as viral hepatitis, schistosomiasis, autoimmune, hereditary, drug induced, or decompensated liver cirrhosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Asisstant Professor
Study Record Dates
First Submitted
August 8, 2017
First Posted
August 15, 2017
Study Start
June 1, 2015
Primary Completion
July 1, 2016
Study Completion
November 1, 2016
Last Updated
August 15, 2017
Record last verified: 2017-08